Inositol Hexaniacinate Helps Intermittent Claudication
pain in both groups over the 3-month period, but the changes were statistically significant only in the IHN group. Furthermore, after 3 months, the patients receiving IHN reported significantly greater subjective improvement than did the placebo group. As with Raynaud’s, discussion of the mechanisms involved has led to controversy.
While arterial dilation may be involved, it has been postulated that reduction in fibrinogen, improvement in blood viscosity and resultant improvement in oxygen transport is induced by IHN.28 Kiff studied 80 patients with intermittent claudication over a 3 month period in a double-blind, placebo-controlled trial with IHN at a dosage of 2 grams twice daily. Symptoms, maximum treadmill distance and walking time were assessed. The most significant finding in this study was that reduction of cigarette smoking had a major influence on treadmill measurements. When smoking was factored out of the equation, the IHN group had significant improvement in treadmill distance.5
Tyson found improvement in walking time and number of paces, as measured by stop watch and pedometer, in a group of 86 patients, with statistical significance of IHN over placebo in the most severely effected group.29 Intermittent claudication poses some difficulties in assessment as the exercise, in itself, will benefit both the placebo and the test group. The IHN, in all studies cited above, seemed to have been tolerated as well or better than placebo. Seckfort has reported that in chronic cases of vascular insufficiency, doses up to 1800 mg. daily were administered without noticeable side effect.30
Kathleen A. Head,
Inositol Hexaniacinate: Safer Alternative to Niacin
Alternative Medicine Review